New pharmacotherapy targeting regeneration of airway epithelial cells

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460660
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Musashino University
• Principal Investigator: YAMASHITA Naomi 武蔵野大学, 薬学研究所, 教授 (20239974)
• Research Collaborator: Niikura Yuichi 武蔵野大学, 薬学研究所, 講師 (10615107) ; 石井 崇史 武蔵野大学, 特別研究学生 ; 細木 佳祐 武蔵野大学, 特別研究学生
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: アレルギー・ぜんそく / 細胞・組織 / 臨床 / 薬理学 / 生体分子

Outline of Final Research Achievements

Airway epithelial cells, first-line cells for the barrier and defense mechanisms, play critical roles in pathophysiology of asthma and COPD. In this study, we explored the new therapy targeting repair mechanisms of airway epithelial cells. We showed that secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related peptide-1 (SLURP-1), one of non-neural acetylcholines, was produced by airway epithelial cells and down-regulated airway inflammation. In addition, we clarified that the modification of innate immune pathway in airway epithelial cells was a promising therapy for asthma and COPD

Free Research Field

臨床薬学・アレルギー